83 related articles for article (PubMed ID: 31900501)
21. Gastrointestinal perforation in anti-NXP2 antibody-associated juvenile dermatomyositis: case reports and a review of the literature.
Xu Y; Ma X; Zhou Z; Li J; Hou J; Zhu J; Kang M; Lai J; Li X
Pediatr Rheumatol Online J; 2021 Jan; 19(1):2. PubMed ID: 33407602
[TBL] [Abstract][Full Text] [Related]
22. [Degos' disease: A case report and review of literature].
Wang XW; Liu X; Zeng Z; Li YX
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Aug; 41(4):487-8. PubMed ID: 19727245
[TBL] [Abstract][Full Text] [Related]
23. Juvenile dermatomyositis resembling late-stage Degos disease with gastrointestinal perforations successfully treated with combination of cyclophosphamide and rituximab: case-based review.
Day W; Gabriel C; Kelly RE; Magro CM; Williams JV; Werner A; Gifford L; Lapsia SP; Aguiar CL
Rheumatol Int; 2020 Nov; 40(11):1883-1890. PubMed ID: 31900501
[TBL] [Abstract][Full Text] [Related]
24. Degos disease with dermatomyositis-like phenomenon: a diagnostic dilemma and a therapeutic challenge.
Gupta S; Dogra S; Saikia UN; Yadav S; Kanwar AJ
J Cutan Med Surg; 2011; 15(3):162-6. PubMed ID: 21561585
[TBL] [Abstract][Full Text] [Related]
25. [Köhlmeier-Degos disease (Malignant Atrophic Papulosis): a cause of recurrent multiple intestinal perforations].
Beuran M; Chiotoroiu AL; Morteanu S; Chilie A; Avram M; Roşu O; Vartic M; Creangă C; Mangrău A
Chirurgia (Bucur); 2009; 104(6):765-72. PubMed ID: 20187481
[TBL] [Abstract][Full Text] [Related]
26. Clinical challenges and images in GI. Image 2: Malignant atrophic papulosis (Degos' disease) with systemic manifestations.
Yamaguchi N; Isomoto H; Nakayama T
Gastroenterology; 2008 Nov; 135(5):1464, 1807. PubMed ID: 18851969
[No Abstract] [Full Text] [Related]
27. Small bowel infarcts in Degos disease.
Amaravadi RR; Tran TM; Altman R; Scheirey CD
Abdom Imaging; 2008; 33(2):196-9. PubMed ID: 17435982
[TBL] [Abstract][Full Text] [Related]
28. Malignant Atrophic Papulosis Presenting with Intestinal Perforation: A Case Report.
Paudel A; Bhurtel MR; Gautam A; Gautam A; Bista M; Singh P
JNMA J Nepal Med Assoc; 2023 Jun; 61(262):549-551. PubMed ID: 37464847
[TBL] [Abstract][Full Text] [Related]
29. Gastrointestinal Tract Vasculopathy: Clinicopathology and Description of a Possible "New Entity" With Protean Features.
Louie CY; DiMaio MA; Charville GW; Berry GJ; Longacre TA
Am J Surg Pathol; 2018 Jul; 42(7):866-876. PubMed ID: 29624512
[TBL] [Abstract][Full Text] [Related]
30. Malignant atrophic papulosis with motor aphasia and intestinal perforation: A case report and review of published works.
Hu P; Mao Z; Liu C; Hu X; Kang H; Zhou F
J Dermatol; 2018 Jun; 45(6):723-726. PubMed ID: 29516548
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling.
Deakin CT; Campanilho-Marques R; Simou S; Moraitis E; Wedderburn LR; Pullenayegum E; Pilkington CA;
Arthritis Rheumatol; 2018 May; 70(5):785-793. PubMed ID: 29342499
[TBL] [Abstract][Full Text] [Related]
32. Effective Administration of Rituximab in Anti-MDA5 Antibody-Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review.
Ogawa Y; Kishida D; Shimojima Y; Hayashi K; Sekijima Y
Case Rep Rheumatol; 2017; 2017():5386797. PubMed ID: 29225988
[TBL] [Abstract][Full Text] [Related]
33. Colonic vasculopathy and perforation in the initial presentation of adult dermatomyositis in a patient with improving muscle weakness.
Kibbi N; Bekui A; Buckley LM
BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26759443
[TBL] [Abstract][Full Text] [Related]
34. Successful open abdomen treatment for multiple ischemic duodenal perforated ulcers in dermatomyositis.
Villa R; Costa S; Focchi S; Corbellini C; Vigorelli M; Avesani EC
World J Emerg Surg; 2014; 9():48. PubMed ID: 26085838
[TBL] [Abstract][Full Text] [Related]
35. The role of type I interferons and other cytokines in dermatomyositis.
Arshanapalli A; Shah M; Veerula V; Somani AK
Cytokine; 2015 Jun; 73(2):319-25. PubMed ID: 25541432
[TBL] [Abstract][Full Text] [Related]
36. Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial.
Rider LG; Yip AL; Horkayne-Szakaly I; Volochayev R; Shrader JA; Turner ML; Kong HH; Jain MS; Jansen AV; Oddis CV; Fleisher TA; Miller FW
Clin Exp Rheumatol; 2014; 32(5):689-96. PubMed ID: 25068290
[TBL] [Abstract][Full Text] [Related]
37. Sustained autoimmune mechanisms in dermatomyositis.
Greenberg SA
J Pathol; 2014 Jul; 233(3):215-6. PubMed ID: 24687932
[TBL] [Abstract][Full Text] [Related]
38. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.
Aggarwal R; Bandos A; Reed AM; Ascherman DP; Barohn RJ; Feldman BM; Miller FW; Rider LG; Harris-Love MO; Levesque MC; ; Oddis CV
Arthritis Rheumatol; 2014 Mar; 66(3):740-9. PubMed ID: 24574235
[TBL] [Abstract][Full Text] [Related]
39. The effects of Eculizumab on the pathology of malignant atrophic papulosis.
Magro CM; Wang X; Garrett-Bakelman F; Laurence J; Shapiro LS; DeSancho MT
Orphanet J Rare Dis; 2013 Nov; 8():185. PubMed ID: 24279613
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
